An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone

Condition(s): Relapsing-Remitting Multiple Sclerosis Last Updated: June 10, 2010Completed

ClinicalTrialsFeeds.org

NIH Clinical Trials Results via RSS

236 Clinical Trials for: Beta-interferons, Page 1 of 12

Pharmacokinetics and Pharmacodynamics of the Interferon Beta-1a Produced by Laboratorio Quimico Farmaceutico Bergamo Compared to Interferon Beta-1a (Rebif - Merck Serono) in Healthy Subjects

Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a

Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta

Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b

Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b

Natalizumab De-escalation With Interferon Beta-1b

Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif^® in Healthy Volunteers

Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers

Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?

MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia

Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis

Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma

Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS

An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone

Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease

BEYOND Follow-up: Betaferon^®/Betaseron^® Efficacy Yielding Outcomes of a New Dose

Get These Results via Email or RSS

Subscribe via Web Newsreaders

Clinical Trials by Condition

Clinical Trials by Drug

Clinical Trials for Rare Diseases

Clinical Trials of Dietary Supplements

Clinical Trials by Sponsor

Clinical Trials by Location

About Clinical Trials Research

Site Details

236 Clinical Trials for: Beta-interferons, Page 1 of 12

Pharmacokinetics and Pharmacodynamics of the Interferon Beta-1a Produced by Laboratorio Quimico Farmaceutico Bergamo Compared to Interferon Beta-1a (Rebif - Merck Serono) in Healthy Subjects

Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a

Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta

Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b

Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b

Natalizumab De-escalation With Interferon Beta-1b

Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers

Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers

Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?

MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia

Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis

Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma

Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS

An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone

Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease

BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose

Share Clinical Trials

Get These Results via Email or RSS

Subscribe via Web Newsreaders

Clinical Trials by Condition

Clinical Trials by Drug

Clinical Trials for Rare Diseases

Clinical Trials of Dietary Supplements

Clinical Trials by Sponsor

Clinical Trials by Location

About Clinical Trials Research

Site Details

Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif^® in Healthy Volunteers

BEYOND Follow-up: Betaferon^®/Betaseron^® Efficacy Yielding Outcomes of a New Dose